Tempus AI, Predicta Expand Genomics Test for Blood Cancer
Chicago, Illinois, U.S. | April 15, 2026 Tempus AI, Inc., in collaboration with Predicta Biosciences, has announced the expansion...
Tempus AI
Advertisement
Tempus, Daiichi Sankyo Advance AI in ADC Oncology Trials
CHICAGO, Illinois, March 25, 2026 Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate AI-driven biomarker...
Tempus Study Shows Genomic Profiling Expands Cancer Care
CHICAGO — March 11, 2026 Tempus AI, Inc., a technology company focused on advancing precision medicine through artificial intelligence...
Whitehawk Therapeutics Identifies PTK7 as a Broadly Expressed ADC Target Across Solid Tumors
MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...
Advertisement
